Published in J Infect Dis on October 15, 2010
Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med (2011) 3.78
Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis (2013) 2.50
Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog (2012) 2.02
Norovirus GII.4 strain antigenic variation. J Virol (2010) 1.73
Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J Virol (2011) 1.53
Epidemiology of human noroviruses and updates on vaccine development. Curr Opin Gastroenterol (2014) 1.49
Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. J Infect Dis (2013) 1.47
Replication of human noroviruses in stem cell-derived human enteroids. Science (2016) 1.44
Seroepidemiology of norovirus-associated travelers' diarrhea. J Travel Med (2014) 1.43
Norovirus. Clin Microbiol Rev (2015) 1.41
Norovirus immunity and the great escape. PLoS Pathog (2012) 1.40
Duration of immunity to norovirus gastroenteritis. Emerg Infect Dis (2013) 1.38
Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes. J Virol (2012) 1.36
Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002. J Virol (2011) 1.29
Serological responses to experimental Norwalk virus infection measured using a quantitative duplex time-resolved fluorescence immunoassay. Clin Vaccine Immunol (2011) 1.20
Characterization of emerging GII.g/GII.12 noroviruses from a gastroenteritis outbreak in the United States in 2010. J Clin Microbiol (2011) 1.18
A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles. Immunology (2012) 1.12
Norovirus P particle efficiently elicits innate, humoral and cellular immunity. PLoS One (2013) 1.10
Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus. Clin Vaccine Immunol (2011) 1.10
Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial. PLoS Med (2015) 1.09
Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine (2011) 1.07
The state of norovirus vaccines. Clin Infect Dis (2014) 1.05
Persistent enteric murine norovirus infection is associated with functionally suboptimal virus-specific CD8 T cell responses. J Virol (2013) 1.05
Norovirus vaccine development: next steps. Expert Rev Vaccines (2012) 1.03
Multiple antigenic sites are involved in blocking the interaction of GII.4 norovirus capsid with ABH histo-blood group antigens. J Virol (2012) 1.02
Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PLoS One (2013) 1.02
Serological Correlates of Protection against a GII.4 Norovirus. Clin Vaccine Immunol (2015) 1.01
Human norovirus transmission and evolution in a changing world. Nat Rev Microbiol (2016) 1.01
Within-host evolution results in antigenically distinct GII.4 noroviruses. J Virol (2014) 0.99
Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus. Nanomedicine (Lond) (2012) 0.99
Characterization of blockade antibody responses in GII.2.1976 Snow Mountain virus-infected subjects. J Virol (2013) 0.98
Antibody responses to norovirus genogroup GI.1 and GII.4 proteases in volunteers administered Norwalk virus. Clin Vaccine Immunol (2012) 0.97
Mucosal and Cellular Immune Responses to Norwalk Virus. J Infect Dis (2015) 0.96
Deep sequencing of norovirus genomes defines evolutionary patterns in an urban tropical setting. J Virol (2014) 0.94
An outbreak caused by GII.17 norovirus with a wide spectrum of HBGA-associated susceptibility. Sci Rep (2015) 0.94
Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings. Mucosal Immunol (2014) 0.93
Identification of a Broadly Cross-Reactive Epitope in the Inner Shell of the Norovirus Capsid. PLoS One (2013) 0.92
Correlates of Protection against Norovirus Infection and Disease-Where Are We Now, Where Do We Go? PLoS Pathog (2016) 0.90
Evaluation of anti-norovirus IgY from egg yolk of chickens immunized with norovirus P particles. J Virol Methods (2012) 0.89
Particle conformation regulates antibody access to a conserved GII.4 norovirus blockade epitope. J Virol (2014) 0.88
Correlates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges. Hum Vaccin Immunother (2014) 0.87
Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio cholerae. Hum Vaccin Immunother (2015) 0.86
Norovirus immunology: Of mice and mechanisms. Eur J Immunol (2015) 0.85
Structural basis of glycan interaction in gastroenteric viral pathogens. Curr Opin Virol (2014) 0.85
Experimental human infection with Norwalk virus elicits a surrogate neutralizing antibody response with cross-genogroup activity. Clin Vaccine Immunol (2014) 0.84
Intranasal vaccination with murabutide enhances humoral and mucosal immune responses to a virus-like particle vaccine. PLoS One (2012) 0.84
Chimeric GII.4 norovirus virus-like-particle-based vaccines induce broadly blocking immune responses. J Virol (2014) 0.83
Branched-linear and agglomerate protein polymers as vaccine platforms. Biomaterials (2014) 0.83
Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs. J Virol (2014) 0.83
Static and Evolving Norovirus Genotypes: Implications for Epidemiology and Immunity. PLoS Pathog (2017) 0.82
Norovirus vaccines and potential antinorovirus drugs: recent advances and future perspectives. Future Virol (2015) 0.82
Vaccine against norovirus. Hum Vaccin Immunother (2014) 0.79
Antigenic Relatedness of Norovirus GII.4 Variants Determined by Human Challenge Sera. PLoS One (2015) 0.79
A trivalent vaccine candidate against hepatitis E virus, norovirus, and astrovirus. Vaccine (2016) 0.78
Immunogenicity of Newcastle disease virus vectors expressing Norwalk virus capsid protein in the presence or absence of VP2 protein. Virology (2015) 0.77
Frequent Use of the IgA Isotype in Human B Cells Encoding Potent Norovirus-Specific Monoclonal Antibodies That Block HBGA Binding. PLoS Pathog (2016) 0.77
TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines. Hum Vaccin Immunother (2013) 0.77
Multiple consecutive norovirus infections in the first 2 years of life. Eur J Pediatr (2015) 0.77
Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition. Clin Vaccine Immunol (2015) 0.77
Antiviral targets of human noroviruses. Curr Opin Virol (2016) 0.77
Heat shock protein 70 enhances mucosal immunity against human norovirus when coexpressed from a vesicular stomatitis virus vector. J Virol (2014) 0.76
Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine. Hum Vaccin Immunother (2016) 0.76
A dual chicken IgY against rotavirus and norovirus. Antiviral Res (2012) 0.76
Newly isolated mAbs broaden the neutralizing epitope in murine norovirus. J Gen Virol (2014) 0.76
Llama nanoantibodies with therapeutic potential against human norovirus diarrhea. PLoS One (2015) 0.75
Norovirus Gastroenteritis in a Birth Cohort in Southern India. PLoS One (2016) 0.75
Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody. Proc Natl Acad Sci U S A (2016) 0.75
Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens. Antiviral Res (2016) 0.75
Norovirus-Specific Memory T Cell Responses in Adult Human Donors. Front Microbiol (2016) 0.75
Norovirus vaccines: Correlates of protection, challenges and limitations. Hum Vaccin Immunother (2016) 0.75
B-Cell Responses to Intramuscular Administration of a Bivalent Virus-like Particle Human Norovirus Vaccine. Clin Vaccine Immunol (2017) 0.75
Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulation. Vaccine (2016) 0.75
Human sera collected during 1979-2010 possess blocking antibody titers to pandemic GII.4 noroviruses isolated during 3 decades. J Virol (2017) 0.75
Food-related illness and death in the United States. Emerg Infect Dis (1999) 39.22
Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol (1992) 8.35
Human susceptibility and resistance to Norwalk virus infection. Nat Med (2003) 7.07
Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis (2002) 5.09
Clinical immunity in acute gastroenteritis caused by Norwalk agent. N Engl J Med (1977) 4.80
Norwalk virus infection of volunteers: new insights based on improved assays. J Infect Dis (1994) 4.37
Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology (2002) 4.13
Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol (2005) 3.74
Norwalk virus shedding after experimental human infection. Emerg Infect Dis (2008) 3.70
Norwalk virus-like particle hemagglutination by binding to h histo-blood group antigens. J Virol (2003) 3.15
Norovirus and its histo-blood group antigen receptors: an answer to a historical puzzle. Trends Microbiol (2005) 3.00
Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J Virol (2002) 2.98
Norovirus disease: changing epidemiology and host susceptibility factors. Trends Microbiol (2004) 2.83
Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis (1990) 2.63
Comparison of the reactivities of baculovirus-expressed recombinant Norwalk virus capsid antigen with those of the native Norwalk virus antigen in serologic assays and some epidemiologic observations. J Clin Microbiol (1993) 2.58
Atomic resolution structural characterization of recognition of histo-blood group antigens by Norwalk virus. Proc Natl Acad Sci U S A (2008) 2.54
Viral shape-shifting: norovirus evasion of the human immune system. Nat Rev Microbiol (2010) 2.53
Attachment and entry of recombinant Norwalk virus capsids to cultured human and animal cell lines. J Virol (1996) 2.51
The epidemiologic and clinical importance of norovirus infection. Gastroenterol Clin North Am (2006) 2.49
Norwalk virus infection associates with secretor status genotyped from sera. J Med Virol (2005) 2.34
Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine (2006) 1.74
Heterotypic humoral and cellular immune responses following Norwalk virus infection. J Virol (2009) 1.70
Noroviruses distinguish between type 1 and type 2 histo-blood group antigens for binding. J Virol (2008) 1.65
Expression and self-assembly of norwalk virus capsid protein from venezuelan equine encephalitis virus replicons. J Virol (2002) 1.60
Anti-carbohydrate antibodies of normal sera: findings, surprises and challenges. Mol Immunol (2009) 1.56
Herd immunity to GII.4 noroviruses is supported by outbreak patient sera. J Virol (2009) 1.51
Acquisition of serum antibody to Norwalk Virus and rotavirus and relation to diarrhea in a longitudinal study of young children in rural Bangladesh. J Infect Dis (1982) 1.46
Viral shedding and fecal IgA response after Norwalk virus infection. J Infect Dis (1995) 1.41
Detection of immunoglobulin M (IgM), IgA, and IgG Norwalk virus-specific antibodies by indirect enzyme-linked immunosorbent assay with baculovirus-expressed Norwalk virus capsid antigen in adult volunteers challenged with Norwalk virus. J Clin Microbiol (1994) 1.33
Booster vaccinations: can immunologic memory outpace disease pathogenesis? Pediatrics (2009) 1.28
Evidence of immunity induced by naturally acquired rotavirus and Norwalk virus infection on two remote Panamanian islands. J Infect Dis (1985) 1.08
Isotype-specific detection of ABO blood group antibodies using a novel flow cytometric method. Br J Haematol (2005) 1.07
Serological responses among teenagers after natural exposure to Norwalk virus. J Infect Dis (1984) 0.92
Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut (2012) 12.62
Traces of human migrations in Helicobacter pylori populations. Science (2003) 11.92
Norovirus gastroenteritis. N Engl J Med (2009) 7.66
Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis (2002) 5.09
Laboratory efforts to cultivate noroviruses. J Gen Virol (2004) 4.41
Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG). Arch Virol (2011) 3.87
Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med (2002) 3.86
Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med (2011) 3.78
Norwalk virus shedding after experimental human infection. Emerg Infect Dis (2008) 3.70
Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol (2005) 3.34
Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology (2002) 3.27
Norwalk virus-like particle hemagglutination by binding to h histo-blood group antigens. J Virol (2003) 3.15
The peopling of the Pacific from a bacterial perspective. Science (2009) 3.14
Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. J Clin Gastroenterol (2012) 2.99
Gastroesophageal reflux among different racial groups in the United States. Gastroenterology (2004) 2.87
Norovirus disease: changing epidemiology and host susceptibility factors. Trends Microbiol (2004) 2.83
Recommendations for the classification of group A rotaviruses using all 11 genomic RNA segments. Arch Virol (2008) 2.77
Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) (2002) 2.75
Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood. Lancet (2002) 2.71
Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2003) 2.59
Helicobacter pylori in North and South America before Columbus. FEBS Lett (2002) 2.57
Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol (2005) 2.54
Atomic resolution structural characterization of recognition of histo-blood group antigens by Norwalk virus. Proc Natl Acad Sci U S A (2008) 2.54
Rotavirus antigenaemia and viraemia: a common event? Lancet (2003) 2.51
Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis (2013) 2.50
The epidemiologic and clinical importance of norovirus infection. Gastroenterol Clin North Am (2006) 2.49
Noroviruses everywhere: has something changed? Curr Opin Infect Dis (2006) 2.44
Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis (2006) 2.43
The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis (2005) 2.43
A report card to grade Helicobacter pylori therapy. Helicobacter (2007) 2.41
The 3' end of Norwalk virus mRNA contains determinants that regulate the expression and stability of the viral capsid protein VP1: a novel function for the VP2 protein. J Virol (2003) 2.38
Structural requirements for the assembly of Norwalk virus-like particles. J Virol (2002) 2.38
Norwalk virus infection associates with secretor status genotyped from sera. J Med Virol (2005) 2.34
Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology (2002) 2.32
Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol (2009) 2.15
X-ray structure of a native calicivirus: structural insights into antigenic diversity and host specificity. Proc Natl Acad Sci U S A (2006) 2.09
Rotaviruses: from pathogenesis to vaccination. Gastroenterology (2009) 2.05
Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med (2011) 2.04
Comparing the Blatchford and pre-endoscopic Rockall score in predicting the need for endoscopic therapy in patients with upper GI hemorrhage. Gastrointest Endosc (2010) 2.04
Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology (2005) 2.03
Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter (2009) 2.02
Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol (2011) 1.98
Magnet ingestions in children presenting to US emergency departments, 2002-2011. J Pediatr Gastroenterol Nutr (2013) 1.98
Gastritis staging in clinical practice: the OLGA staging system. Gut (2006) 1.90
Complications of pediatric EGD: a 4-year experience in PEDS-CORI. Gastrointest Endosc (2007) 1.89
Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol (2003) 1.89
Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J Infect (2005) 1.83
Neonatal infection with G10P[11] rotavirus did not confer protection against subsequent rotavirus infection in a community cohort in Vellore, South India. J Infect Dis (2007) 1.83
Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine (2003) 1.83
Inter- and intragenus structural variations in caliciviruses and their functional implications. J Virol (2004) 1.79
Risk factors for immediate and delayed bleeding associated with endoscopic submucosal dissection of gastric neoplastic lesions. Scand J Gastroenterol (2009) 1.75
NSAIDs, Helicobacter pylori, and Pandora's Box. N Engl J Med (2002) 1.75
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter (2011) 1.73
Noroviruses: The leading cause of gastroenteritis worldwide. Discov Med (2010) 1.73
Discrimination between cases of duodenal ulcer and gastritis on the basis of putative virulence factors of Helicobacter pylori. J Clin Microbiol (2002) 1.72
Evolutionary trace residues in noroviruses: importance in receptor binding, antigenicity, virion assembly, and strain diversity. J Virol (2005) 1.71
Human rhinovirus proteinase 2A induces TH1 and TH2 immunity in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol (2010) 1.69
Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer (2002) 1.69
Biliary stenting in the management of large or multiple common bile duct stones. Gastrointest Endosc (2010) 1.68
Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med (2006) 1.68
Norwalk virus RNA is infectious in mammalian cells. J Virol (2007) 1.66
Cell attachment protein VP8* of a human rotavirus specifically interacts with A-type histo-blood group antigen. Nature (2012) 1.65
Norwalk virus-specific binding to oyster digestive tissues. Emerg Infect Dis (2006) 1.63
Management of gastric polyps: a pathology-based guide for gastroenterologists. Nat Rev Gastroenterol Hepatol (2009) 1.62
The prevalence of suspected Barrett's esophagus in children and adolescents: a multicenter endoscopic study. Gastrointest Endosc (2006) 1.60
Role of interferon-stimulated responsive element-like element in interleukin-8 promoter in Helicobacter pylori infection. Gastroenterology (2004) 1.59
Helicobacter pylori infection in mice: Role of outer membrane proteins in colonization and inflammation. Gastroenterology (2002) 1.58
Iron deficiency and Helicobacter pylori infection in the United States. Am J Epidemiol (2005) 1.57
Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res (2002) 1.56
Replication and packaging of Norwalk virus RNA in cultured mammalian cells. Proc Natl Acad Sci U S A (2005) 1.56
Endoscopic demonstration of transient small bowel intussusception in a patient with adult celiac disease. Gastrointest Endosc (2003) 1.55
Identification of Genogroup I and Genogroup II broadly reactive epitopes on the norovirus capsid. J Virol (2005) 1.53
Structural analysis of histo-blood group antigen binding specificity in a norovirus GII.4 epidemic variant: implications for epochal evolution. J Virol (2011) 1.53
Comparative study of the epidemiology of rotavirus in children from a community-based birth cohort and a hospital in South India. J Clin Microbiol (2006) 1.51
Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol (2012) 1.51
Rising incidence of inflammatory bowel disease among children: a 12-year study. J Pediatr Gastroenterol Nutr (2010) 1.51
Aichi virus, norovirus, astrovirus, enterovirus, and rotavirus involved in clinical cases from a French oyster-related gastroenteritis outbreak. J Clin Microbiol (2008) 1.50
Epidemiology of human noroviruses and updates on vaccine development. Curr Opin Gastroenterol (2014) 1.49
Rotavirus architecture at subnanometer resolution. J Virol (2008) 1.48